Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models
- 228 Downloads
Osteosarcoma chemotherapy is often limited by chemoresistance, resulting in poor prognosis. Combined chemotherapy could, therefore, be used to prevent resistance to chemotherapeutics. Here, the effects of fisetin on osteosarcoma cells were investigated, as well as cytostatic potential in combination with the anti-cancer drug etoposide. For this, different osteosarcoma cell lines were treated with fisetin, with etoposide and with respective combinations. Fisetin was associated with decrease in colony formation in Saos-2 and in U2OS cells but not in MG-63 cells. Notwithstanding, upon evaluation of cellular growth by crystal violet assay, MG-63 and Saos-2 cells showed decreased cell proliferation at 40 and 20 µM fisetin, respectively. Depending on the relative concentrations, fisetin:etoposide combinations showed negative-to-positive interactions on the inhibition of cell proliferation. In addition, fisetin treatment up to 50 µM for 48 h resulted in G2-phase cell cycle arrest. Regardless of the combination, fisetin:etoposide increased % cells in G2-phase and decreased % cells in G1-phase. In addition, mixtures with more positive combined effects induced increased % cells in S-phase. Compared to etoposide treatment, these combinations resulted in decreased levels of cyclins B1 and E1, pointing to the role of these regulators in fisetin-induced cell cycle arrest. In conclusion, these results show that the combination of fisetin with etoposide has higher anti-proliferative effects in osteosarcoma associated with cell cycle arrest, allowing the use of lower doses of the chemotherapeutic agent, which has important implications for osteosarcoma treatment.
KeywordsOsteosarcoma P53 Combination therapy Fisetin Etoposide Cell cycle regulators MG-63 cells Saos-2 cells
This work was supported by Grants from the Portuguese Foundation for Science and Technology—Fundação para a Ciência e a Tecnologia (SFRH/BPD/74868/2010 to J.M.P.F.O, SFRH/BPD/111736/2015 to H.O.).
Compliance with ethical standards
The manuscript does not contain clinical studies or patient data.
Conflict of interest
The authors declare that they have no conflict of interest.
- Chen YC, Shen SC, Lee WR et al (2002) Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 76:351–359. https://doi.org/10.1007/s00204-002-0346-6 CrossRefPubMedGoogle Scholar
- Chou TC, Martin N (2005) CompuSyn for drug combinations: PC software and user’s guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values. ComboSyn Inc, ParamusGoogle Scholar
- Lee JD, Huh JE, Jeon GS et al (2009) Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int Immunopharmacol 9:268–276. https://doi.org/10.1016/j.intimp.2008.11.005 CrossRefPubMedGoogle Scholar
- Li J, Cheng Y, Qu W et al (2011) Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol 108:84–93. https://doi.org/10.1111/j.1742-7843.2010.00613.x CrossRefPubMedGoogle Scholar
- Pal HC, Sharma S, Elmets CA et al (2013) Fisetin inhibits growth, induces G2/M arrest and apoptosis of human epidermoid carcinoma A431 cells: role of mitochondrial membrane potential disruption and consequent caspases activation. Exp Dermatol 22:470–475. https://doi.org/10.1111/exd.12181.Fisetin CrossRefPubMedPubMedCentralGoogle Scholar
- Sung B, Pandey MK, Aggarwal BB (2007) Fisetin, an inhibitor of cyclin-dependent kinase 6, down—regulates nuclear factor-κB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein—regulated IκBα kinase activ. Mol Pharmacol 71:1703–1714. https://doi.org/10.1124/mol.107.034512 CrossRefPubMedGoogle Scholar
- Syed DN, Afaq F, Maddodi N et al (2011) Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. J Invest Dermatol 131:1291–1299. https://doi.org/10.1038/jid.2011.6 CrossRefPubMedPubMedCentralGoogle Scholar
- Touil YS, Auzeil N, Saighi H et al (2011a) Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite. 82:1731–1739. https://doi.org/10.1016/j.bcp.2011.07.097
- Touil YS, Seguin J, Scherman D, Chabot GG (2011b) Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol 68:445–455. https://doi.org/10.1007/s00280-010-1505-8 CrossRefPubMedGoogle Scholar
- Zhao S, Fernald RD (2005) Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 12:1047–1064. https://doi.org/10.1089/cmb.2005.12.1047.Comprehensive CrossRefPubMedPubMedCentralGoogle Scholar